Thymostimulin versus placebo for palliative treatment of locally advanced or metastasised hepatocellular carcinoma: a phase III clinical trial

BACKGROUND: Thymostimulin is a thymic peptide fraction with immune-mediated cytotoxicity against hepatocellular carcinoma (HCC) in vitro and palliative efficacy in advanced HCC in two independent phase II trials. The aim of this study was to assess the efficacy of thymostimulin in a phase III trial....

Descripción completa

Detalles Bibliográficos
Autores principales: Dollinger, Matthias M, Lautenschlaeger, Christine, Lesske, Joachim, Tannapfel, Andrea, Wagner, Anna-Dorothea, Schoppmeyer, Konrad, Nehls, Oliver, Welker, Martin-Walter, Wiest, Reiner, Fleig, Wolfgang E
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2936330/
https://www.ncbi.nlm.nih.gov/pubmed/20735834
http://dx.doi.org/10.1186/1471-2407-10-457

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2936330/
https://www.ncbi.nlm.nih.gov/pubmed/20735834
http://dx.doi.org/10.1186/1471-2407-10-457

Ejemplares similares